Not yet recruiting
Lip and/or oral cavity cancer+1
Not yet recruitingStudy of neoadjuvant intratumoral ipilimumab combined with systemic nivolumab in patients with locally advanced resectable oral cavity squamous cell carcinoma
Registered drugNo placebo
Study of neoadjuvant intratumoral ipilimumab combined with systemic nivolumab in patients with locally advanced resectable oral cavity squamous cell carcinoma
Registered drugNo placebo
- Substances:IpilimumabNivolumab
Countries:
The Netherlands
The Netherlands- Participants:18–64 years · 65+ years
- Substances:Ipilimumab
